TB-500 Neuroprotection Research: Thymosin Beta-4 in Stroke and Brain Injury Models

The stroke dose-response, and why it is non-monotonic

TB-500 neuroprotection research traces to thymosin beta-4, and its sharpest result is a dose curve that goes the wrong way at the top. In male Wistar rats with embolic middle cerebral artery occlusion, intraperitoneal Tβ4 given at 2, 12, or 18 mg/kg starting 24 hours post-stroke — then every three days for four more doses — improved neurological function at 2 and 12 mg/kg, significant from day 14 through day 56 (p<0.05); 18 mg/kg gave no significant benefit ^[4]. The authors modeled an optimal dose near ~3.75 mg/kg.

That is the panel worth pausing on. Higher was not better. The benefit appeared at the low and middle doses and vanished at the high one — a non-monotonic response that directly undercuts community "loading" rationales, which assume more peptide means more effect. These are animal-study parameters, not a human dose, and they are on the full-length protein.

A companion report in Neuroscience found that thymosin beta-4 improved functional neurological outcome in a rat model of embolic stroke, consistent with the dose-response work ^[8].

Traumatic brain injury and axon regeneration

Beyond stroke, thymosin beta-4 stroke and brain-injury models extend to trauma. Thymosin beta-4 treatment produced neuroprotective and neurorestorative effects in a rat model of traumatic brain injury, improving functional outcome ^[7]. The mechanism story stays anchored to actin: a 2024 zebrafish study showed that thymosin beta-4 promotes Mauthner-axon regeneration by facilitating actin dynamics ^[12] — the same 1:1 G-actin biology established structurally for the parent protein ^[1], now tied to a regenerative neuro endpoint.

Actin sequestration regulates the cytoskeletal remodeling that growing axons and migrating cells depend on, which is the throughline linking the wound, cardiac, and neuro literatures: one mechanism, several tissues.

What the neuro record does not establish

Every neuro finding above is animal-only, and most are on full-length Tβ4 rather than the TB-500 7-mer. There is no human efficacy data for TB-500 in stroke, brain injury, or any neurological condition. Injectable Tβ4 stroke trials were registered, but an early injectable acute-stroke trial was withdrawn, so a presumed clinical pipeline overstates the current evidence.

The honest summary: in rodents and zebrafish, the parent protein improves neurological recovery and promotes axon regeneration through actin dynamics, with a dose-response that peaks and then falls. Whether the isolated fragment does any of this in humans is unstudied.